Last updated: 4 months ago
Telix Pharmaceuticals Limited: December 2024 Form 6-K Report Highlights Progress in Kidney Cancer Diagnostics
Explore Telix Pharmaceuticals' December 2024 Form 6-K report featuring BLA filing for TLX250-CDx and CEO remuneration updates. Key insights for investors and stakeholders.